HomeFor professionalsDOAC-CVT study


DOAC-CVT is an international, prospective, phase IV cohort study investigating use of safety and efficacy of direct oral anticoagulants (DOACs) instead of vitamin K antagonists (VKA) in treatment of the cerebral venous thrombosis.

We will include data from patients who fulfill the following criteria:

  • Age >18 years at the time of CVT diagnosis
  • Radiologically confirmed CVT diagnosis (CT-venography, MRI or catheter angiography)
  • Oral anticoagulant treatment (DOAC or VKA) started within 30 days of CVT diagnosis (patient may initially be treated with heparin)
  • Informed consent for the use of coded data if required by local law.

Exclusion criteria:

  • Anticoagulant treatment at the time of CVT diagnosis
  • Pregnancy or lactation (post-partum women are eligible if they do not give breast-feeding)
  • Mechanical heart valve
  • Severe renal insufficiency (defined as an eGFR <15 ml/min)
  • Severe liver disease resulting in clinically relevant coagulopathy

If you have a case and want to participate in this research project, please e-mail the project leader, Jonathan Coutinho.

Include a new patient

Acces to online CRF must be provided by study coördinators.